Most recent patent granted on Oct. 24, 2019
Over the past two decades, GW Pharmaceuticals (GWPH) has been granted multiple patents related to the use of cannabinoids in specific medical conditions, including cancer.
The following patents have been granted in the past 18 months:
GRANTED October 24, 2019.
Patent related to pharmaceutical formulations containing cannabinoids for administration via a pump action spray.
Prevention and treatment of neurodegenerative diseases, e.g. Alzheimer’s.
GRANTED April 16, 2019.
Patent includes: cannabichromene (CBC), cannabidivarin (CBDV) and/or cannabidivarin acid (CBDVA).
Processes and apparatus for extraction of active substances and enriched extracts from natural products.
GRANTED: February 5, 2019.
Processes for preparing extracts of natural products such as plant material, and for preparing purified extracts from crude extracts of natural products, by extraction with hot gas. Apparatus suitable for use in preparing extracts of natural products are also described.
GRANTED: January 15, 2019.
Pharmaceutical formulations, and more particularly to formulations containing cannabinoids for administration via a pump action spray. In particular, the invention relates to pharmaceutical formulations, for use in administration of lipophilic medicaments via mucosal surfaces.
Active pharmaceutical ingredient comprising cannabinoids for use in treatment of cancer
Two particularly favored API combinations are: cannabidiol (CBD) and cannabigerol (CBG); and cannabidiolic (CBD) and tetrahydrocannabivarin (THCV)
GRANTED: May 8, 2018.
Relates to an active pharmaceutical ingredient which comprises or consists essentially of CBD and one other cannabinoid selected from cannabigerol (CBG), cannabigerolic acid (CBGA), cannabidiolic acid (CBDA), and tetrahydrocannabivarin (THCV) for use as a medicament, and more particularly, for use in the treatment of cancer.
These combinations have shown themselves to be synergistic in treating one or more of: breast cancer; liver cancer; lung cancer; pancreatic cancer; melanoma; ovarian cancer; gastric cancer; renal cancer or bladder cancer.
Two particularly favored API combinations are: cannabidiol (CBD) and cannabigerol (CBG); and cannabidiolic (CBD) and tetrahydrocannabivarin (THCV).